XTL Biopharmaceuticals Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.8M
- Price
- $2.78
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.66%
- Volume
- 520
About
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
Quick stats
Shares outstanding2.5M
Computed float2.5M
Float / shares100.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001023549
Websitehttps://www.xtlbio.com
AI Summary
AI-generated1/6
majormixedm and a
XTL Completed the Acquisition of Psyga Bio Ltd.
XTL Biopharmaceuticals completed its acquisition of Psyga Bio Ltd., acquiring 83.40% of Psyga's share capital and pivoting XTL into a dedicated psychedelic medicine company with clinical-stage psilocybin-based assets.
The acquisition was funded through stock-based consideration representing approximately 33.36% of XTL's post-issuance capital, with up to an additional 25.02% contingent on three clinical and commercial milestones, resulting in substantial shareholder dilution.
XTL gains a licensed GMP manufacturing facility, a proprietary library of over 250 mushroom strains, and a clinical pipeline targeting treatment-resistant depression, PTSD, anorexia, and addictions, developed in partnership with Professor Dedi Meiri.
A concurrent $1.5M private placement was wired to the company's treasury, while a pending Nasdaq delisting determination and delayed 2025 annual filing remain material overhangs.
Red flags
- Pending Nasdaq delisting determination disclosed in risk factors
- Significant dilution: 33.36% of capital post-issuance, up to additional 25.02% from milestones
- 2025 annual financial statements (Form 20-F) not yet filed as of June 30, 2026
- Clinical-stage assets with no current revenue